Caplacizumab clinical trials
Also written ALX-0081.
How each study uses caplacizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 6 Feb 2019 · CABLIVI · BLA 761112 (FDA, Drugs@FDA)
- European Union
- 30 Aug 2018 · Cablivi · EMEA/H/C/004426 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Ablynx, a Sanofi company (4) · Sanofi (3) · University Hospital, Rouen (1)
Studies
Open first, then newest update. How each study uses caplacizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTPTerminatedPhase 2University Hospital, RouenNCT04720261Written as Caplacizumab
- Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraCompletedPhase 3SanofiNCT05468320Written as Caplacizumab
- A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)CompletedPhase 2/3SanofiNCT04074187Written as Caplacizumab (ALX-0081)
- Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic PurpuraCompletedPhase 3Ablynx, a Sanofi companyNCT02553317Written as Caplacizumab
- Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)CompletedPhase 2Ablynx, a Sanofi companyNCT01151423Written as Caplacizumab
- Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) PatientsCompletedPhase 2Ablynx, a Sanofi companyNCT01020383Written as ALX-0081
- Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)CompletedPhase 3SanofiNCT02878603Written as Caplacizumab
- Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.CompletedPhase 1Ablynx, a Sanofi companyNCT02189733Written as Caplacizumab
Codes
What other systems call caplacizumab · ClinicalTrials.gg INT006401
- MeSH (NLM) C585343caplacizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2R27AB6766CAPLACIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2110605Confirmed FDA, Wikidata
- Wikidata Q5036030caplacizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C128625CaplacizumabOne source FDA
- DrugBank DB06081One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585343 | caplacizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2R27AB6766 | CAPLACIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2110605 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5036030 | caplacizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C128625 | Caplacizumab | One source FDA |
| DrugBank | DB06081 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.